Adjuvant imatinib therapy for gastrointestinal stromal tumors

Journal of Surgical Oncology

Volumn 104, Issue 8, 2011, Pages 896-900

  Pisters, Peter W T ^a   Colombo, Chiara ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

adjuvant therapy; adverse events; gastrointestinal stromal tumor; GIST; imatinib; risk stratification

Indexed keywords

CARBAMAZEPINE; DEXAMETHASONE; IMATINIB; PHENOBARBITAL; PHENYTOIN; PLACEBO; RIFABUTIN; RIFAMPICIN;

ABDOMINAL PAIN; ADJUVANT THERAPY; ANEMIA; ARTICLE; BLEEDING; CHRONIC MYELOID LEUKEMIA; DERMATITIS; DIARRHEA; DRUG WITHDRAWAL; EDEMA; FATIGUE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL STROMAL TUMOR; GRANULOCYTOPENIA; HEADACHE; HUMAN; MYALGIA; NAUSEA AND VOMITING; NEUTROPENIA; PRIORITY JOURNAL; RASH; RECURRENT DISEASE; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; PIPERAZINES; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA;

EID: 80855139422     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.22002     Document Type: Article

References (53)

1. Casali PG, Jost L, Reichardt P, et al.: ESMO Guidelines Working Group. Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008; 19: ii35-ii38.
2. Nilsson B, Bümming P, Meis-Kindblom JM, et al.: Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era-A population-based study in western Sweden. Cancer 2005; 103: 821-829. (Pubitemid 40216412)
3. Goettsch WG, Bos SD, Breekveldt-Postma N, et al.: Incidence of gastrointestinal stromal tumours is underestimated: Results of a nation-wide study. Eur J Cancer 2005; 41: 2868-2872. (Pubitemid 41713125)
4. DeMatteo RP, Lewis JJ, Leung D, et al.: Two hundred gastrointestinal stromal tumors: Recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231: 51-58. (Pubitemid 30043939)
5. Thuneberg L,: One hundred years of interstitial cells of Cajal. Microsc Res Tech 1999; 47: 223-238.
6. Reichardt P, Blay JY, von Menren M,: Towards a global consensus in the treatment of gastrointestinal stromal tumor. Expert Rev Anticancer Ther 2010; 10: 221-232.
7. Buchdunger E, Cioffi CL, Law N, et al.: Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295: 139-145.
8. Druker BJ, Tamura S, Buchdunger E, et al.: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561-566.
9. Hirota S, Isozaki K, Moriyama Y, et al.: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577-580. (Pubitemid 28067289)
10. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al.: Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344: 1052-1056. (Pubitemid 32267975)
11. Verweij PJ, Casali PG, Zalcberg PJ, et al.: Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial. Lancet 2004; 364: 1127-1134. (Pubitemid 39296599)
12. Van Oosterom AT, Judson I, Verweij J, et al.: European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study. Lancet 2001; 358: 1421-1423.
13. Verweij J, van Oosterom A, Blay JY, et al.: Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 2003; 39: 2006-2011. (Pubitemid 37297756)
14. DeMatteo RP, Owzar K, Antonescu CR, et al.: Efficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST) at high risk of recurrence: The U.S. Intergroup phase II trial ACOSOG Z9000. Presented at: American Society of Clinical Oncology 2008 Gastrointestinal Cancers Symposium; January 25-27, 2008; Orlando, Fla.
15. Nilsson B, Sjolund K, Kindblom LG, et al.: Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST). Br J Cancer 2007; 96: 1656-1658. (Pubitemid 46847213)
16. DeMatteo R, Ballmann KV, Antonescu CR, et al.: Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: A randomised, double-blind, placebo-controlled trial. Lancet 2009; 373: 1097-1104.
17. Demetri GD, Benjamin RS, Blanke CD, et al.: NCCN Task Force report: Management of patients with gastrointestinal stromal tumor (GIST)-Update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw 2007; 5: S1-S29.
18. Joensuu H, Fletcher C, Dimitrijevic S, et al.: Management of malignant gastrointestinal stromal tumours. Lancet Oncol 2002; 3: 655-664. (Pubitemid 35314908)
19. Roberts PJ, Eisenberg B,: Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease. Eur J Cancer 2002; 38: S37-S38.
20. DeMatteo RP, Heinrich MC, El-Rifai WM, et al.: Clinical management of gastrointestinal stromal tumors: Before and after STI-571. Hum Pathol 2002; 33: 466-477. (Pubitemid 34747865)
21. Pierie JP, Choudry U, Muzikansky A, et al.: The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch Surg 2001; 136: 383-389. (Pubitemid 32322809)
22. Rossi CR, Mocellin S, Mencarelli R, et al.: Gastrointestinal stromal tumors: From a surgical to a molecular approach. Int J Cancer 2003; 107: 171-176. (Pubitemid 37152893)
23. Miettenen M, Makhlouf H, Sobin LH, et al.: Gastrointestinal stromal tumors of the jejunum and ileum: A clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol 2006; 30: 477-489. (Pubitemid 43740149)
24. Casali PG, Jost L, Reichardt P, et al.: ESMO Guidelines Working Group. Gastrointestinal stromal tumours: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20: 64-67.
25. Demetri GD, von Mehren M, Antonescu CR, et al.: NCCN Task Force report: Update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw 2010; 8: S1-S41.
26. Novartis Pharmaceuticals Corporation. Imatinib [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2002.
27. Dutreix C, Peng B, Mehring G, et al.: Ketoconazole increases imatinib (Glivec®/STI571) exposure: Results of a drug-drug interaction study. Blood 2002; 100: 214b.
28. O'Brien SG, Meinhardt P, Bond E, et al.: Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia. Br J Cancer 2003; 89: 1855-1859. (Pubitemid 37533259)
29. Judson I, Ma P, Peng B, et al.: Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: A retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol 2005; 55: 379-386. (Pubitemid 40379262)
30. Blanke C, Rankin C, Demetri GD, et al.: Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the KIT receptor tyrosine kinase: S0033. J Clin Oncol 2008; 26: 626-632. (Pubitemid 351264358)
31. Van Glabbeke M, Verweij J, Casali PG, et al.: Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: A study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG). Eur J Cancer 2006; 42: 2277-2285. (Pubitemid 44316904)
32. Druker BJ, Talpaz M, Resta DJ, et al.: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037. (Pubitemid 32267972)
33. Miettinen M, Lasota J,: Gastrointestinal stromal tumors: Pathology and prognosis at different sites. Sem Diagn Pathol 2006; 23: 70-83. (Pubitemid 44692418)
34. Fletcher CD,: Clinicopathologic correlations in gastrointestinal stromal tumors. Hum Pathol 2002; 33: 455. (Pubitemid 34747862)
35. DeMatteo RP, Gold JS, Saran L, et al.: Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer 2008; 112: 608-615. (Pubitemid 351186201)
36. Gold JS, Gönen M, Gutiérrez A, et al.: Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: A retrospective analysis. Lancet Oncol 2009; 10: 1045-1055.
37. Miettinen M, Lasota J,: Gastrointestinal stromal tumors-definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001; 438: 1-12. (Pubitemid 32128184)
38. Blay JY, Le Cesne A, Ray-Coquard I, et al.: Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: The French Sarcoma Group. J Clin Oncol 2007; 25: 1107-1113. (Pubitemid 46596763)
39. Le Cesne A, Ray-Coquard I, Bui B, et al.: Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumors after 3 years of treatment: An open label multicentre randomised phase 3 trial. Lancet Oncol 2010; 11: 942-949.
40. Demetri GD, von Mehren M, Blanke CD, et al.: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-480. (Pubitemid 34879334)
41. Antonescu CR, Besmer P, Guo T, et al.: Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 2005; 11: 4182-4190. (Pubitemid 40791584)
42. Debiec-Rychter M, Cools J, Dumez H, et al.: Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of PKC412 against imatinib-resistant mutants. Gastroenterology 2005; 128: 270-279. (Pubitemid 40431080)
43. Wakai T, Kanda T, Hirota S, et al.: Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a second KIT mutation. Br J Cancer 2004; 90: 2059-2061. (Pubitemid 38869705)
44. FDA: "FDA Approves New Treatment for Gastrointestinal and Kidney Cancer." January 26, 2006. December 8, 2010 (date of access).
45. Demetri GD, Casali PG, Blay JY, et al.: A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Clin Cancer Res 2009; 15: 5910-5916.
46. Shah NP, Tran C, Lee FY, et al.: Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305: 399-401. (Pubitemid 38938156)
47. Heinrich MC, Corless CL, Demetri GD, et al.: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21: 4342-4349. (Pubitemid 46621810)
48. Debiec Rychter M, Sciot R, Le Cesne A, et al.: KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006; 42: 1093-1103. (Pubitemid 44275331)
49. Heinrich MC, Corless CL, Blanke CD, et al.: Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006; 24: 4764-4774. (Pubitemid 46630941)
50. Hirota S, Ohashi A, Nishida T, et al.: Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 2003; 125: 660-667. (Pubitemid 37070684)
51. Heinrich MC, Shoemaker JS, Corless CL, et al.: Correlation of target kinase genotype with clinical activity of imatinib mesylate (IM) in patients with metastatic GI stromal tumors (GISTs) expressing KIT (KIT1. J Clin Oncol 2005; 23: 7.
52. Antonescu CR, Sommer G, Sarran L, et al.: Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res 2003; 9: 3329-3337. (Pubitemid 37082727)
53. Singer S, Rubin BP, Lux ML, et al.: Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol 2002; 20: 3898-3905.